Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Compare

3,561 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SRPT Analyst Ratings

Strong Buy

19 Buy

5 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$94.18

▲(138.19%Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $94.18 with a high forecast of $188.00 and a low forecast of $40.00. The average price target represents a 138.19% change from the last price of $39.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","189":"$189","74.25":"$74.3","112.5":"$112.5","150.75":"$150.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$188.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,74.25,112.5,150.75,189],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.74,49.29846153846154,60.85692307692308,72.41538461538462,83.97384615384615,95.53230769230768,107.09076923076924,118.64923076923077,130.2076923076923,141.76615384615386,153.32461538461538,164.8830769230769,176.44153846153847,{"y":188,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.74,42.081538461538464,46.42307692307693,50.76461538461538,55.106153846153845,59.44769230769231,63.78923076923077,68.13076923076923,72.4723076923077,76.81384615384616,81.15538461538462,85.49692307692308,89.83846153846153,{"y":94.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.74,37.91384615384616,38.08769230769231,38.261538461538464,38.43538461538461,38.60923076923077,38.783076923076926,38.956923076923076,39.13076923076923,39.30461538461539,39.47846153846154,39.652307692307694,39.826153846153844,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":129.86,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.75,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$188.00

Average Price Target$94.18

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$41

Hold

3.69%

Upside

Reiterated

06/05/25

The overall score reflects significant financial health challenges, with strong revenue growth offset by negative profitability and cash flow issues. Technical analysis signals bearish momentum, and the stock's valuation indicates potential overvaluation. Despite a positive demand outlook, short-term challenges remain due to safety incidents and administrative delays.

Louise ChenScotiabank

Scotiabank

$80

Buy

102.33%

Upside

Upgraded

06/05/25

Sarepta upgraded to Outperform from Sector Perform at ScotiabankSarepta upgraded to Outperform from Sector Perform at Scotiabank

Kostas BiliourisBMO Capital

BMO Capital

$120

Buy

203.49%

Upside

Reiterated

06/05/25

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/04/25

Buy Rating on Sarepta Therapeutics Driven by FDA Platform Technology Designation

Salveen RichterGoldman Sachs

Goldman Sachs

$100

Buy

152.91%

Upside

Reiterated

05/28/25

Goldman Sachs Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$40

Hold

1.16%

Upside

Reiterated

05/22/25

Sarepta Therapeutics: Navigating Clinical Holds and Regulatory Challenges Amidst Market Expansion Uncertainty

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/21/25

Optimistic Outlook for Sarepta Therapeutics Amid Positive Developments in ENVISION Study and Strategic Partnerships

Anupam RamaJ.P. Morgan

J.P. Morgan

$169→$84

Buy

112.44%

Upside

Reiterated

05/19/25

Buy Rating on Sarepta Therapeutics: Valuation Disconnect and Growth Potential Highlighted by Elevidys Approval

Andrew TsaiJefferies

Jefferies

$165→$125

Buy

216.14%

Upside

Reiterated

05/16/25

Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations

Michael UlzMorgan Stanley

Morgan Stanley

$113

Buy

185.79%

Upside

Reiterated

05/13/25

Morgan Stanley on Sarepta (SRPT): Elevidys Approval in Japan Further Confirms Favorable Benefit/Risk ProfileMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $113.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

Uy EarMizuho Securities

Mizuho Securities

$190→$85

Buy

114.97%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and TransMedics Group (NASDAQ: TMDX)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$123→$50

Hold

26.45%

Upside

Downgraded

05/08/25

Sarepta downgraded to In Line from Outperform at Evercore ISISarepta downgraded to In Line from Outperform at Evercore ISI

Tazeen AhmadBank of America Securities

Bank of America Securities

$157→$76

Buy

92.21%

Upside

Reiterated

05/08/25

Sarepta Therapeutics: Buy Rating Affirmed Amid Challenges and Recovery Prospects

Yanan ZhuWells Fargo

Wells Fargo

$115→$100

Buy

152.91%

Upside

Reiterated

05/08/25

Sarepta Therapeutics (SRPT) PT Lowered to $100 at Wells FargoWells Fargo analyst Yanan Zhu lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $100.00 (from $115.00) while maintaining a Overweight rating.

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$163→$81

Buy

104.86%

Upside

Reiterated

05/07/25

Sarepta Therapeutics (SRPT) PT Lowered to $81 at Cantor FitzgeraldCantor Fitzgerald analyst Kristen Kluska lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $81.00 (from $163.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$41

Hold

3.69%

Upside

Reiterated

06/05/25

Louise ChenScotiabank

Scotiabank

$80

Buy

102.33%

Upside

Upgraded

06/05/25

Sarepta upgraded to Outperform from Sector Perform at ScotiabankSarepta upgraded to Outperform from Sector Perform at Scotiabank

Kostas BiliourisBMO Capital

BMO Capital

$120

Buy

203.49%

Upside

Reiterated

06/05/25

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/04/25

Buy Rating on Sarepta Therapeutics Driven by FDA Platform Technology Designation

Salveen RichterGoldman Sachs

Goldman Sachs

$100

Buy

152.91%

Upside

Reiterated

05/28/25

Goldman Sachs Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$40

Hold

1.16%

Upside

Reiterated

05/22/25

Sarepta Therapeutics: Navigating Clinical Holds and Regulatory Challenges Amidst Market Expansion Uncertainty

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/21/25

Optimistic Outlook for Sarepta Therapeutics Amid Positive Developments in ENVISION Study and Strategic Partnerships

Anupam RamaJ.P. Morgan

J.P. Morgan

$169→$84

Buy

112.44%

Upside

Reiterated

05/19/25

Buy Rating on Sarepta Therapeutics: Valuation Disconnect and Growth Potential Highlighted by Elevidys Approval

Andrew TsaiJefferies

Jefferies

$165→$125

Buy

216.14%

Upside

Reiterated

05/16/25

Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations

Michael UlzMorgan Stanley

Morgan Stanley

$113

Buy

185.79%

Upside

Reiterated

05/13/25

Uy EarMizuho Securities

Mizuho Securities

$190→$85

Buy

114.97%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and TransMedics Group (NASDAQ: TMDX)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$123→$50

Hold

26.45%

Upside

Downgraded

05/08/25

Sarepta downgraded to In Line from Outperform at Evercore ISISarepta downgraded to In Line from Outperform at Evercore ISI

Tazeen AhmadBank of America Securities

Bank of America Securities

$157→$76

Buy

92.21%

Upside

Reiterated

05/08/25

Sarepta Therapeutics: Buy Rating Affirmed Amid Challenges and Recovery Prospects

Yanan ZhuWells Fargo

Wells Fargo

$115→$100

Buy

152.91%

Upside

Reiterated

05/08/25

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$163→$81

Buy

104.86%

Upside

Reiterated

05/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

1 Month

xxx

Success Rate

30/46 ratings generated profit

Average Return

+3.08%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +3.08% per trade.

3 Months

xxx

Success Rate

21/37 ratings generated profit

Average Return

+7.51%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.76% of your transactions generating a profit, with an average return of +7.51% per trade.

1 Year

Brian SkorneyRobert W. Baird

Success Rate

30/46 ratings generated profit

Average Return

+9.57%

reiterated a buy rating last month

Copying Brian Skorney's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +9.57% per trade.

2 Years

xxx

Success Rate

20/46 ratings generated profit

Average Return

-7.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 43.48% of your transactions generating a profit, with an average return of -7.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SRPT has received 45 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. SRPT average Analyst price target in the past 3 months is 94.18.

Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $0.86 with a range of -$0.49 to $2.41. The previous quarter’s EPS was -$4.60. SRPT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SRPT has Outperformed its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $557.48M with a range of $525.97M to $646.48M. The previous quarter’s sales results were $744.86M. SRPT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year SRPT has Outperformed its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 94.18.

What is SRPT’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 138.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Strong Buy which is based on 19 buy ratings, 5 hold ratings and 0 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is 94.18. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $188.00 ,the lowest forecast is $40.00. The average price target represents 138.19% Increase from the current price of $39.54.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts